TW300881B - - Google Patents

Download PDF

Info

Publication number
TW300881B
TW300881B TW084106325A TW84106325A TW300881B TW 300881 B TW300881 B TW 300881B TW 084106325 A TW084106325 A TW 084106325A TW 84106325 A TW84106325 A TW 84106325A TW 300881 B TW300881 B TW 300881B
Authority
TW
Taiwan
Prior art keywords
carnitine
patent application
salt
economic affairs
glycolate
Prior art date
Application number
TW084106325A
Other languages
English (en)
Original Assignee
Avantgarde Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avantgarde Spa filed Critical Avantgarde Spa
Application granted granted Critical
Publication of TW300881B publication Critical patent/TW300881B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365Hydroxycarboxylic acids; Ketocarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/006Antidandruff preparations
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)

Description

經濟部中央標準局員工消费合作社印製 A7 B7 五、發明説明(1 ) 【發明說明】 本發明關於一種新穎的L -肉毒鹼鹽及使用其製造口 服,尤其是丸粒、片劑、錠劑、膠囊、粉末等等形式的固 體組成物。 熟知L 一肉毒鹸鹽本身具有各種治療用途。 例如,L—肉毒鹸已經用於心與血管領域,於治療急 性及慢性心肌缺血、狹心症、心律不整及心官能不足。在 腎病學中,L —肉毒鹼已經用在給薬予尿毒症病患,該病 患受到規則之血液透析處理以便能消解肌肉無力及肌肉痙 孿之發作。 更進一步之治療用途係將全部腸外營養中的HD L/ LD L+VLDL比率回復到正常。 亦已知道肉毒鹼鹽具有與那些所謂的^內鹽'相同之 治療活性,而因此可用於代替之,倘若它們是,藥學上可 接"鹽。因此實務上,、內鹽與真正肉毒鹼鹽間的選擇 係大部分視何化合物可較易地或較經濟地取得及在藥學科 技的考量而定,而非在於治療活性的考量。所以,例如, (見美國專利第4,9 6 8,7 1 9號)適合的藥學上可 接受鹽包括酸加成鹽且可含有當作陰離子的:醋酸鹽、己 二酸鹽、藻酸鹽、天門冬酸鹽、苯甲酸鹽、苯磺酸鹽、硫 酸氫鹽、檸檬酸鹽、樟腦酸鹽、樟腦磺酸鹽、環戊烷丙酸 鹽、二葡糖酸鹽、十二磺酸鹽、乙磺酸鹽、延胡索酸鹽、 氯化物、溴化物、碘化物、2 -羥乙磺酸鹽、乳酸鹽、順 丁烯二酸鹽、甲磺酸鹽、2 -某磺酸鹽、菸鹸酸鹽、草酸 本紙張尺度適用中國國家梯準(CNS ) A4規格(210X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
-4 - 經濟部中央標準局貝工消费合作社印製 A7 B7 五、發明説明(2 ) 鹽、棕櫚酸鹽、果膠酸鹽、過硫酸鹽、3 —苯基丙酸鹽、 苦味酸鹽、三甲基乙酸鹽、琥珀酸鹽、酒石酸鹽、硫氰酸 鹽、甲苯磺酸鹽、十二酸鹽等等。 最近,愈來愈多的不必經過醫師處方即可購買的含L 一肉毒鹼之製劑上市上,經過科學根據之認可:L -肉毒 鹸對運動員在供應肌肉能量以及增進耐力和壓力容忍度有 顯著貢獻。此外L 一肉毒鹸係素食者不可缺少的營養供給 物,素食者的飲食中肉毒鹼及兩種胺基酸(離胺酸及甲硫 胺酸)不足,其爲人體肝及腎中L -肉毒鹸生物合成的前 體。 因此,該些消費者中有產生對適當形式的給藥,尤其 是口服製劑且較佳爲固體配方之需求。 已知,L-肉毒鹼內鹽係一種高吸濕性化合物,因此 不易於儲存、處理及複合,尤其是製造固體給藥形式時。 此外,因爲微量三甲胺之存在,所以L_肉毒鹼常有難聞 之魚腥味。 將L 一肉毒鹼轉化成非吸濕性之藥學上可接受鹽的問 題已經獲得解決。例如,歐洲專利第0 150 688 號揭示一些該鹽一列如L -肉毒鹸酸延胡索酸鹽之製備。 本發明之目的在於提供一種新穎的非濕性、穩定性及 無臭味的L 一肉毒鹼之藥學上可接受鹽,即式(I ) L 一 肉毒鹸甘醇酸鹽: 本紙張尺度適用中國國家標準(CNS > A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁)
-5 - 經濟部中央標準局員工消費合作社印製 3G0881 at B7 五、發明説明(3 )
COCH (I) 此新穎鹽可易於被儲存及加工成穩定的固體口服製劑 ,尤其適於運動員及素食者之營養供給。此係令人驚異地 ,因爲甘醇酸係有些吸濕性的。 L 一肉毒鹼甘醇酸鹽可如下製備得: 眚例 L 一肉毒鹼甘醇酸鹽(ST 1 1 36)之製備 將L —肉毒鹼內鹽(16. 1克;0· 1莫耳)溶解 於100毫升水中。將甘醇酸(7. 6克;0. 1莫耳) 加入該溶液中。 於4 0°C真空下濃縮所得溶液》用異丙醇吸收所形成 殘留物,及將固體濾出。得到2 3克。 從熱的異丙醇中結晶出化合物。 熔點=112. 3 °C (DSC) 元素分析:CeH17NOe _C % Η % Ν % 本紙張尺度逋用中國國家標準(CNS > Α4規格(210X297公釐) ^ϋ'—m· ^^^1 HI m n^i 1_ 1^- ^^^1 n^i (請先閱讀背面之注意事項再填寫本頁) -6 - 經濟部中央標準局貝工消費合作社印製 A7 B7 五、發明説明(4 ) 計算值 4 5 . 9 5 7 . 2 8 5 . 9 5 實測值 4 6 . 17 8 . 4 6 6 . 0 6 水含量 0.3% ρ Η = 3 - 9 ία) « = 1 9 . 9〇 (c = 1%,H20)
H P L C
管柱:Ai BondapackH (ΙΟίίηι) 30〇mmx 3 . 9mm 溫度:3 0 °C 流動相:CHaCN/KHaPO^mM ρ H 5 . 2 6 5/35 流速:1. 0毫升/分鐘 甘醇酸=4. 91分鐘31. 6% L —肉毒鹸鹽111:=8. 99分鐘68. 4% NMR D 2 Ο δ 4. 5-4. 4(lH«m- C Η Ο Η) ; 3 . 9 ( 2 Η - s > C Η g Ο Η ) ; 3 . 3 (2H,m,CH2N + ) ; 3 . l(9H,s,( C Η a ) a Ν + ) ; 2 . 4(2H,dd,CH2COO) 對L -肉毒鹼甘醇酸鹽作吸濕性測試,而爲了比較之 緣故,亦對高吸濕性的L -肉毒鹼內鹽和兩種已知的無吸 濕性L —肉毒鹼鹽即L —肉毒鹸L —酒石酸鹽(見Muller 等人,Hoppe-Sey I er’s Ζ· Ph i s i ο I. Chem. 3 5 3, 本紙張尺度逋用中國國家標準(CNS > A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁)
-7 - 經濟部中央標準局貝工消费合作社印製 A7 _B7 五、發明説明(5 ) 618 — 622 ’ 1972)及L —肉毒鹼酸延胡索酸鹽 (見歐洲專利第1 5 0 6 8 8號)作吸濕性測試。上述 鹽樣品暴露於2 5 °C之9 0%濕度環境中’測量它們在不 同時間的卡耳一費雪(κ· F)指數, 測試結果如下: 卡耳- 費雪指數(在以下時間後) 0 小時 16 小時 24 小時 40 小時 112 小時 L —肉毒鹼內鹽 0.20 3.40 4.40 7.60 12.90 L 一肉毒鹼L 一 0. 30 0.30 0.30 0. 30 0. 50 酒石酸鹽 L —肉毒鹼延胡 0.50 0. 50 0. 75 0. 82 0.91 索酸鹽 L 一肉毒鹸甘醇 0.30 0.50 0.50 0. 50 0.50 酸鹽 依本發明,片劑、丸粒、膠囊、錠劑等等可以含有以下成 分:黏合劑,如微晶纖維素、西黃蓍樹膠或明膠;賦形劑 ,如澱粉或乳糖;崩散劑,如海藻酸、普利摩膠( 本紙張尺度適用中國國家揉準(CNS ) Α4規格(210Χ297公釐) ' -8 - (請先閣讀背面之注意事項再填寫本頁)
300881 A7 _______B7 五、發明説明(6 )
Prim〇gei)、玉米澱粉等等;潤滑劑,如硬脂酸鎂或司特 若得斯(Sterotes);助流劑,如膠體二氧化矽;甜味劑 ’如蔗糖或糖精,或調味劑,如薄荷、水楊酸甲酯或橘 香料。當劑量單元形式係膠囊時,其除了上述種類材料外 *尙可含有液體載體’如脂肪油。其它劑量單元形式可含 有其它不同之材料,此材料改變劑量單元的物理形式,例 如包衣。因此片劑或丸粒可以塗被有糖、蟲膠、或其它腸 溶衣劑。糖漿除了含有效化合物外尙可含有當作甜味劑的 蔗糖以及一些防腐劑、染料及著色劑和香料。 用於製備該些種種組成物的材料應爲藥學上純的且所 用的量係無毒的。 (請先閲讀背面之注意事項再填寫本«) 訂 經濟部中央梯準局貝工消費合作杜印製 本紙張尺度逋用中國國家標準(CNS ) A4規格(210X297公釐) 一 9 一

Claims (1)

  1. r300^8^1^ B8 fM .fr 产 C8 」..'的丨丨_ 六臭到範圍, 附件一A:第84106325號專利申請案 中文申請專利範圍修正本 民國85年11月修正 1. L一肉毒鹼甘醇酸鹽。 2 ·—種含低吸溼性之L 一肉毒鹸之固態口服用藥學 組成物,其係包含L -肉毒鹼甘醇酸鹽及其藥學上可接受 之載體或賦形劑。 3.如申請專利範圍第2項之組成物,其係爲丸粒、 片劑、錠劑、膠囊或粉末之形式。 4 ·如申請專利範圍第3項之組成物,其更含有至少 —選自下列族群的成員:黏合劑、崩散劑、潤滑劑、助流 劑、流動性調整劑、甜味劑及調味劑。 (請先閱讀背面之注意事項再填寫本頁) 訂 線 經濟部中央梂準局貝工消費合作社印装 本紙張尺度逍用中國國家揲率(CNS > A4規格(210X297公釐)
TW084106325A 1994-06-20 1995-06-20 TW300881B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM940396A IT1272290B (it) 1994-06-20 1994-06-20 Sale della l-carnitina e composizioni farmaceutiche che lo contengono per il trattamento di affezioni cutanee

Publications (1)

Publication Number Publication Date
TW300881B true TW300881B (zh) 1997-03-21

Family

ID=11402602

Family Applications (1)

Application Number Title Priority Date Filing Date
TW084106325A TW300881B (zh) 1994-06-20 1995-06-20

Country Status (13)

Country Link
US (1) US5591450A (zh)
EP (2) EP0688761A2 (zh)
JP (2) JPH0827081A (zh)
KR (2) KR960000855A (zh)
AT (1) ATE165338T1 (zh)
CA (2) CA2150407A1 (zh)
DE (1) DE69502147T2 (zh)
ES (1) ES2116651T3 (zh)
HK (1) HK1004918A1 (zh)
IT (1) IT1272290B (zh)
PH (1) PH31606A (zh)
TW (1) TW300881B (zh)
ZA (2) ZA955025B (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1272290B (it) * 1994-06-20 1997-06-16 Avantgarde Spa Sale della l-carnitina e composizioni farmaceutiche che lo contengono per il trattamento di affezioni cutanee
AUPN115095A0 (en) * 1995-02-15 1995-03-09 Butt, Henry Lawrence Analysis of and compositions and methods for the treatment of disease
IT1276253B1 (it) 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
IT1289974B1 (it) * 1997-02-25 1998-10-19 Aldo Fassi Procedimento per la produzione di sali stabili e non igroscopici di l(-)carnitina e di alcanoli l(-)-carnitine
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US6080788A (en) * 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics
US5863940A (en) 1997-12-01 1999-01-26 Sigma-Tau Healthscience S.P.A. Medicament and therapeutical method for treating idiopathic asthenozoospermia
US6090848A (en) * 1997-12-01 2000-07-18 Sigma-Tau Healthscience S.P.A. Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
ES2210705T5 (es) 1998-03-19 2011-02-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composición combinada que comprende una l-carnitina o una alcanoil-l-carnitina, un glucosaminoglucano y/o un constituyente del mismo.
KR20000050756A (ko) * 1999-01-14 2000-08-05 연규 핀 귀걸이의 제조방법과 그 제품의 구조
US6090849A (en) * 1999-03-23 2000-07-18 The Board Of Regents For Oklahoma State University Carnitine supplemented diet to prevent sudden death syndrome in breeder type poultry
ITRM20010364A1 (it) * 2001-06-25 2002-12-27 Biosalts Srl Ascorbil derivati di carnitine e composizioni cosmetiche contenenti tali derivati.
AU2004226324A1 (en) * 2003-03-28 2004-10-14 Lonza Inc. Topical L-carnitine compositions
JP4539096B2 (ja) * 2004-01-16 2010-09-08 日油株式会社 油性成分被覆l−カルニチン塩粉末およびその用途
CN1322860C (zh) * 2004-08-31 2007-06-27 北京正大绿洲医药科技有限公司 左旋肉碱滴丸及其制备方法
US7572832B2 (en) * 2007-03-19 2009-08-11 Biolink Life Sciences, Inc. Non-hygroscopic L-carnitine salts
KR101633846B1 (ko) 2013-11-25 2016-06-27 주식회사 엘지화학 도전성 패턴 형성용 조성물 및 도전성 패턴을 갖는 수지 구조체
KR20170131506A (ko) * 2015-03-27 2017-11-29 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Mek 키나제 억제제에 대한 p-톨루엔설포네이트 및 이의 결정형 및 이들의 제조 방법
CN107216339B (zh) * 2016-03-22 2021-05-04 中国科学院上海药物研究所 一种dppiv抑制剂马来酸盐的多晶型及其制备方法
CN107216340B (zh) * 2016-03-22 2021-05-04 中国科学院上海药物研究所 一种dppiv抑制剂的盐型及其制备方法
SE542106C2 (en) * 2016-08-26 2020-02-25 Atif M Dabdoub Dietary macro/micronutritional supplement for patients undergoing kidney dialysis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0150688B1 (en) 1983-12-28 1987-04-22 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Salts of l-carnitine and alkanoyl l-carnitines and process for preparing same
FR2627385B3 (fr) * 1988-02-23 1991-08-23 Serobiologiques Lab Sa Composition notamment utile comme matiere de base pour la preparation de compositions pharmaceutiques, notamment dermatologiques et/ou cosmetiques
US4968719A (en) * 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease
US5137910A (en) * 1989-05-05 1992-08-11 C.D. Searle & Co. Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders
IT1263013B (it) * 1992-10-20 1996-07-23 Avantgarde Spa Esteri della l-carnitina e di alcanoil l-carnitine con l'acido glicolico o suoi esteri e composizioni farmaceutiche contenenti tali per il trattamento di affezioni cutanee.
IT1261984B (it) * 1993-06-22 1996-06-11 Avantgarde Spa Uso di esteri della l-carnitina o di acil l- carnitine con idrossiacidi per produrre composizioni farmaceutiche per il trattamento di affezioni cutanee.
IT1272290B (it) * 1994-06-20 1997-06-16 Avantgarde Spa Sale della l-carnitina e composizioni farmaceutiche che lo contengono per il trattamento di affezioni cutanee

Also Published As

Publication number Publication date
EP0697397A1 (en) 1996-02-21
PH31606A (en) 1998-11-03
DE69502147D1 (de) 1998-05-28
CA2152005A1 (en) 1995-12-21
IT1272290B (it) 1997-06-16
KR960000217A (ko) 1996-01-25
EP0688761A2 (en) 1995-12-27
KR960000855A (ko) 1996-01-25
HK1004918A1 (en) 1998-12-11
ATE165338T1 (de) 1998-05-15
ITRM940396A0 (it) 1994-06-20
JPH0826984A (ja) 1996-01-30
DE69502147T2 (de) 1998-08-13
EP0697397B1 (en) 1998-04-22
ES2116651T3 (es) 1998-07-16
CA2150407A1 (en) 1995-12-21
EP0688761A3 (zh) 1996-01-17
ITRM940396A1 (it) 1995-12-20
JPH0827081A (ja) 1996-01-30
US5591450A (en) 1997-01-07
ZA955024B (en) 1996-02-08
ZA955025B (en) 1996-02-08

Similar Documents

Publication Publication Date Title
TW300881B (zh)
TWI331525B (en) Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
US5607969A (en) L-DOPA ethyl ester to treat Parkinson's disease
US10336679B2 (en) Polymorphic forms of sodium benzoate and uses thereof
CA2288287C (en) Solid compositions suitable for oral administration comprising l-carnitine or alkanoyl-l-carnitine magnesium fumarate
TW587937B (en) Pharmaceutical composition for treating diabetes mellitus and conditions associated with diabetes mellitus
JPS62270522A (ja) 尿毒症を治療するための栄養補強物
JP7397563B2 (ja) 固形製剤
AU731316B2 (en) Solid compositions suitable for oral administration comprising L-carnitine and alkanoyl-L-carnitine magnesium tartrate
JP4181406B2 (ja) L−カルニチンおよびアルカノイルl−カルニチンとタウリンクロリドおよびグリシンクロリドとの非吸湿性塩を含有する経口投与に好適な固形組成物
JP2011231022A (ja) イミダゾロン誘導体
US3362879A (en) Tyrosine tranquilizing compositions and methods of treatment
TWI285204B (en) Polymorphs of a crystalline azabicyclo[2,2.2]octan-3-amine citrate and their pharmaceutical compositions
KR19990043995A (ko) 발암억제를 위한 카르보스티릴 유도체의 용도
KR100562055B1 (ko) 2-아미노에탄설폰산과 결합된 l-카르니틴 및 알카노일-l-카르니틴의 비흡습성 염을 함유하는 경구 투여용 고체 조성물
JP2003277260A (ja) 高血圧抑制剤
US3891768A (en) Treatment of Parkinson{3 s disease
MXPA02002141A (es) Sales no-higroscopicas de ingredientes activos que tienen actividades terapeuticas y/o nutricionales y composiciones administrables oralmente que contienen las mismas.
WO2018208647A1 (en) Taste-modified creatine salts, compounds, compositions and uses thereof
JPH02174791A (ja) ニツコマイシン誘導体、ニツコマイシン誘導体の抗真菌性組成物及びアゾール抗真菌剤
JP5086369B2 (ja) テオペデリン誘導体を含有する薬剤学的組成物、健康食品組成物及び誘導型一酸化窒素合成酵素の活性阻害剤組成物
CA2335503A1 (en) Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and alkanoyl l-carnitines
KR20230172013A (ko) 트리엔틴 테트라하이드로클로라이드 및 이의 제조 방법 및 이의 조성물
JPH0256426A (ja) 虚血性脳障害処置剤